Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:39 2024-12-06 am EST			5-day change	1st Jan Change
89.81 ^CHF	-0.63%		-3.71%	+5.82%

Dec. 06	Swiss Market Index Ends Week Little Changed; Holcim Shares Down	MT
Dec. 06	Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy	MT

NOVARTIS AG : Deutsche Bank reaffirms its Neutral rating

October 30, 2024 at 07:09 am EDT

Emmanuel Papadakis from Deutsche Bank retains his Neutral opinion on the stock. The target price is reduced from CHF 105 to CHF 100.

Latest news about Novartis AG

Swiss Market Index Ends Week Little Changed; Holcim Shares Down	Dec. 06	MT
Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy	Dec. 06	MT
Novartis: positive data for Fabhalta in HPN	Dec. 06	CF
Novartis' Rare Blood Disorder Drug Improves Hemoglobin Levels in Phase 3b Trial	Dec. 06	MT
New Phase IIIB data shows Novartis Fabhalta(R) improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy	Dec. 06	DJ
Novartis Announces Positive Topline Results from APPULSE-PNH, a Phase IIIB Study Evaluating the Efficacy and Safety of Two-Daily Oral Monotherapy Fabhalta	Dec. 06	CI
NOVARTIS AG : Deutsche Bank remains Neutral	Dec. 05	ZD
US Court Rejects Novartis' Appeal to Block Heart Failure Drug's Generic Version	Dec. 04	MT
Novartis cannot block generic of best-selling heart drug, US appeals court says	Dec. 04	RE
HSBC Downgrades Novartis to Reduce, Price Target is $95	Dec. 04	MT
NOVARTIS AG : JP Morgan reiterates its Neutral rating	Dec. 03	ZD
Sector Update: Health Care Stocks Slipping Late Afternoon	Dec. 02	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate	Dec. 02	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
Novartis AG, PTC Therapeutics, Inc. - M&A Call	Dec. 02
Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement	Dec. 02	MT
PTC Therapeutics Shares Jump on Pact With Novartis	Dec. 02	DJ
PTC Therapeutics Signs Exclusive Global License Deal With Novartis Unit for PTC518 Huntington's Disease Program; Shares Rise Premarket	Dec. 02	MT
Swiss Market Index Recovers; Nestlé Shares Edge Up	Nov. 27	MT
Global markets live: HP, Dell, Amazon, EasyJet, HSBC...	Nov. 27
Novartis Receives European Commission Approval for Adjuvant Early Breast Cancer Treatment	Nov. 27	MT
Novartis Wins EU Approval for Expanded Use of Kisqali in Breast Cancer Treatment	Nov. 27	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

12:30pm - American Society of Hematology Meeting - Abstract Number - 67

More about the company